IL6 and hemolytic-uremic syndrome: The pathophysiology behind the development of HUS as a complication of PEP is not fully understood but it is proposed that endothelial damage from inflammatory mediators (such as tumor necrosis factor‐alpha, interleukin‐1 [IL‐1], IL‐6, and IL‐18) released from the inflamed pancreas may trigger this condition.4